Rice Hall James & Associates LLC Has Lowered Holding in Nektar Therapeutics (NKTR) by $12.27 Million as Valuation Rose

April 17, 2018 - By Marie Mckinney

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.19 in Q4 2017. Its down 0.21, from 1.4 in 2017Q3. It dropped, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Rice Hall James Assoc Ltd Company stated it has 2.42% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Pnc Fincl Serv Group accumulated 49,330 shares. California State Teachers Retirement System invested in 0.03% or 233,964 shares. Parametric Portfolio Assocs Limited Liability Company has 432,295 shares for 0.03% of their portfolio. Profund Advisors Ltd Liability Co invested in 0.19% or 80,937 shares. Great West Life Assurance Company Can invested 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Metropolitan Life Insur New York invested in 0.04% or 45,958 shares. State Teachers Retirement, New York-based fund reported 285,000 shares. Los Angeles Capital Management Equity Research Incorporated holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 39,070 shares. Qs Ltd Co holds 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 3,612 shares. 99,255 were reported by Sector Pension Invest Board. Rhumbline Advisers has 369,568 shares. Balyasny Asset Mgmt Limited Com reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% in Nektar Therapeutics (NASDAQ:NKTR). 48,259 were reported by Clarivest Asset Mgmt Limited Com.

Since December 13, 2017, it had 0 buys, and 17 selling transactions for $66.98 million activity. ROBIN HOWARD W had sold 83,333 shares worth $4.64 million on Wednesday, December 13. CHESS ROBERT sold 25,000 shares worth $2.30 million. Shares for $2.77 million were sold by GREER R SCOTT on Friday, April 6. 220,144 shares were sold by Nicholson John, worth $21.85M. KUEBLER CHRISTOPHER A sold 30,000 shares worth $1.76 million. Doberstein Stephen K also sold $14.89M worth of Nektar Therapeutics (NASDAQ:NKTR) shares.

Rice Hall James & Associates Llc decreased its stake in Nektar Therapeutics (NKTR) by 16.81% based on its latest 2017Q4 regulatory filing with the SEC. Rice Hall James & Associates Llc sold 207,977 shares as the company’s stock rose 80.22% while stock markets declined. The institutional investor held 1.03M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $61.47M, down from 1.24M at the end of the previous reported quarter. Rice Hall James & Associates Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $15.07 billion market cap company. The stock increased 0.20% or $0.19 during the last trading session, reaching $93.66. About 1.85M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 17, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Rice Hall James & Associates Llc, which manages about $1.51B and $2.54B US Long portfolio, upped its stake in Strayer Education Inc. (NASDAQ:STRA) by 38,216 shares to 167,728 shares, valued at $15.03M in 2017Q4, according to the filing. It also increased its holding in Criteo S.A. Adr (NASDAQ:CRTO) by 141,241 shares in the quarter, for a total of 938,770 shares, and has risen its stake in Tetra Tech Inc. (NASDAQ:TTEK).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 EPS, down 2.38 % or $0.01 from last year’s $-0.42 per share. After $-0.14 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14 % negative EPS growth.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 7 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 12 analyst reports since October 18, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, April 2 by H.C. Wainwright. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Canaccord Genuity on Wednesday, January 10. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Jefferies on Wednesday, October 18. The rating was maintained by Roth Capital on Monday, November 13 with “Buy”. Mizuho maintained Nektar Therapeutics (NASDAQ:NKTR) on Friday, April 6 with “Buy” rating. The firm earned “Buy” rating on Wednesday, November 8 by Jefferies. Cowen & Co maintained Nektar Therapeutics (NASDAQ:NKTR) on Monday, April 9 with “Buy” rating. On Thursday, March 29 the stock rating was maintained by Mizuho with “Buy”. The rating was initiated by Canaccord Genuity on Thursday, November 9 with “Buy”. PiperJaffray maintained the stock with “Overweight” rating in Friday, April 13 report.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: